Vaxcyte, Inc. (PCVX) Covered Calls

Vaxcyte, Inc. is a clinical-stage vaccine innovation company developing high-fidelity vaccines to prevent serious bacterial diseases. The company’s proprietary XpressCF cell-free protein synthesis platform allows for the design of broad-spectrum conjugate vaccines with enhanced immunogenicity. Its lead candidate, VAX-31, is a 31-valent pneumococcal conjugate vaccine (PCV) aiming to set a new standard in protection against invasive pneumococcal disease for both adults and infants.

You can sell covered calls on Vaxcyte, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for PCVX (prices last updated Tue 4:16 PM ET):

Vaxcyte, Inc. (PCVX) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
61.35 +1.09 55.61 61.00 792K - 7.9
Covered Calls For Vaxcyte, Inc. (PCVX)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Mar 20 60 4.30 56.70 5.8% 84.7%
Apr 17 60 5.50 55.50 8.1% 55.8%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

Vaxcyte is a biotechnology firm dedicated to re-engineering the way complex vaccines are manufactured. The company’s core technology is the XpressCF platform, a cell-free protein synthesis system licensed from Sutro Biopharma. This platform enables Vaxcyte to bypass the limitations of traditional cell-based manufacturing, allowing for the precise, site-specific conjugation of a higher number of antigens without sacrificing the vaccine’s overall immune response. This "carrier-sparing" approach is the foundation of their lead product candidate, VAX-31.

VAX-31 is a 31-valent pneumococcal conjugate vaccine designed to cover approximately 95% of the serotypes causing invasive pneumococcal disease (IPD) in U.S. adults. By early 2026, Vaxcyte has advanced VAX-31 into a pivotal Phase 3 program, including the OPUS-1 non-inferiority trial. The pipeline also includes VAX-24, a 24-valent candidate, and earlier-stage programs targeting Group A Strep (VAX-A1), Shigella (VAX-GI), and periodontal disease (VAX-PG). The company is currently building out dedicated commercial-scale manufacturing lines in partnership with Lonza and Thermo Fisher Scientific to support its future product launches.

Competitive Landscape

The vaccine market is dominated by a few massive pharmaceutical entities with established distribution networks. Vaxcyte’s primary competition comes from incumbents in the pneumococcal space, specifically Pfizer (with Prevnar 20) and Merck (with Capvaxive). Within the biotechnology and pharmaceutical sectors, primary competitors listed on the NYSE or NASDAQ with active, liquid options chains include Pfizer Inc., Merck & Co., GSK plc, and BioNTech SE. Additionally, the company is often compared to other high-growth biotech innovators like Moderna, which are also exploring next-generation vaccine platforms.

Strategic Outlook and Innovation

Vaxcyte’s strategy for 2026 is centered on completing the pivotal data readouts for VAX-31 to support a planned Biologics License Application (BLA) submission by 2027. A key area of innovation is the company’s "site-specific conjugation" technique, which ensures that each antigen is attached to the carrier protein in a way that maximizes the visibility of the pathogen to the human immune system. This technology is expected to give Vaxcyte a "best-in-class" profile, potentially outperforming existing vaccines that rely on more random, less efficient conjugation methods.

Strategically, the company is shifting from a purely R&D-focused organization to one ready for commercial scale. This involves the completion of its custom fill-finish manufacturing lines in North Carolina, which will provide the infrastructure necessary for a global rollout. Vaxcyte also intends to initiate pediatric Phase 3 trials for VAX-31 in 2026, following positive Phase 2 results in infants. With a multi-billion dollar cash runway, the firm is well-positioned to fund its clinical milestones and navigate the regulatory approval process without the immediate need for dilutive financing. The long-term goal is to replace the current standard-of-care with a more comprehensive, higher-valency solution that addresses the evolving landscape of bacterial resistance.